MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. 

About Cardiomyopathies

Heartbeats: A Conversation with The Hypertrophic Cardiomyopathy Experts

News & Events

January 3, 2017
MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi

December 2, 2016
MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491

December 1, 2016
MyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer

November 11, 2016
MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients